Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Psyence Group Inc. (C:PSYG)

Business Focus: Biotechnology & Medical Research (NEC)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
Company Contact
Address: 121 Richmond Street West
, Penthouse Suite, 1300
TORONTO ON M5H 2K1
Tel: N/A
Website: https://www.psyence.com
IR: See website
Key People
Jody Aufrichtig
Executive Chairman of the Board
Adri Botha
Interim Chief Financial Officer
 
Business Overview
Psyence Group Inc. is a Canada-based life science biotechnology company with a focus on natural psychedelics. The Company is focused on the research, cultivation and production of psychedelics and nature-based compounds to treat psychological trauma in the context of palliative care and in support of mental wellness. It cultivates natural psilocybin mushrooms (Psilocybe Cubensis) at its federally licensed ISO22000 facility in Southern Africa. The Company's divisions include Psyence Production, Psyence Therapeutics and Psyence Function. Psyence Therapeutics develops natural psilocybin products, medicinal formulations and treatment protocols to treat mental health disorders in a clinical environment. Psyence Production operates federally licensed ISO22000 certified psilocybin cultivation and production facilities in the world. Psyence Function is focused on the development, distribution and sale of over-the-counter functional mushroom nutraceutical products.
Financial Overview
For the nine months ended 31 December 2023, Psyence Group Inc revenues decreased from C$6K to C$0K. Net loss applicable to common stockholders decreased 29% to C$2.4M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Sales and marketing decrease of 92% to C$21K (expense), General and administrative decrease of 24% to C$443K (expense).
Employees: 21 as of Dec 31, 2005
Reporting Currency: Canadian Dollars
Enterprise value: $2.53M as of Dec 31, 2023
Annual revenue (TTM): $-0.01M as of Dec 31, 2023
EBITDA (TTM): -$6.21M as of Dec 31, 2023
Net annual income (TTM): -$5.13M as of Dec 31, 2023
Free cash flow (TTM): -$4.18M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 139,106,226 as of Mar 11, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization